ANDA 91090, held by Glenmark Pharms Ltd. Norethindrone Acetate.
As of Nov 16, 2026, ANDA 91090 (Norethindrone Acetate), held by Glenmark Pharms Ltd, was first approved by FDA on Jul 21, 2010, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Norethindrone acetate is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 21, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norethindrone Acetate5MG · tablet;oral | Norethindrone Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters